CD44: A Multifunctional Mediator of Cancer Progression.

Tytuł:: CD44: A Multifunctional Mediator of Cancer Progression.
Autorzy:: Hassn Mesrati M; Nanobiotechnology Research Group, Department of Biochemistry, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Serdang 43400 UPM, Selangor, Malaysia.
Syafruddin SE; UKM Medical Molecular Biology Institute (UMBI), Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur 56000, Malaysia.
Mohtar MA; UKM Medical Molecular Biology Institute (UMBI), Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur 56000, Malaysia.
Syahir A; Nanobiotechnology Research Group, Department of Biochemistry, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Serdang 43400 UPM, Selangor, Malaysia.; UPM-MAKNA Cancer Research Laboratory, Institute of Bioscience, Universiti Putra Malaysia, Serdang 43400 UPM, Selangor, Malaysia.
Źródło:: Biomolecules [Biomolecules] 2021 Dec 09; Vol. 11 (12). Date of Electronic Publication: 2021 Dec 09.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't; Review
Język:: English
Imprint Name(s):: Original Publication: Basel, Switzerland : MDPI, 2011-
MeSH Terms:: Alternative Splicing*
Hyaluronan Receptors/*genetics
Neoplasms/*pathology
Disease Progression ; Epithelial-Mesenchymal Transition ; Gene Expression Regulation, Neoplastic ; Humans ; Hyaluronan Receptors/metabolism ; Neoplasm Grading ; Neoplasm Staging ; Neoplasms/genetics ; Neoplasms/metabolism ; Neoplastic Stem Cells/metabolism ; Prognosis ; Survival Analysis
References:: J Cell Physiol. 1997 May;171(2):152-60. (PMID: 9130462)
Cancer Cell Int. 2017 Jan 5;17:8. (PMID: 28070170)
Cancer Res. 2012 Jul 1;72(13):3414-23. (PMID: 22552294)
PLoS One. 2014 Feb 19;9(2):e88712. (PMID: 24586375)
Cell Signal. 2012 Feb;24(2):549-559. (PMID: 22024282)
Oncol Lett. 2019 Oct;18(4):3698-3704. (PMID: 31516582)
Sci Rep. 2018 Oct 8;8(1):14913. (PMID: 30297743)
Nat Med. 2011 Feb;17(2):211-5. (PMID: 21240262)
Int J Oncol. 2017 Sep;51(3):771-780. (PMID: 28677740)
Oncologist. 2008 Nov;13(11):1155-65. (PMID: 18997126)
Cell Stem Cell. 2014 Mar 6;14(3):357-69. (PMID: 24607407)
J Cancer. 2019 Jul 25;10(19):4499-4508. (PMID: 31528214)
Cancer Cell Int. 2013 Nov 20;13(1):117. (PMID: 24257075)
Connect Tissue Res. 1989;23(2-3):123-36. (PMID: 2698313)
Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Dec;116(6):743-51. (PMID: 24237725)
Sci Rep. 2018 Sep 3;8(1):13143. (PMID: 30177680)
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013 Dec;157(4):280-3. (PMID: 23235720)
Cell Death Dis. 2020 Apr 23;11(4):266. (PMID: 32327629)
Cancer Res. 1999 May 15;59(10):2329-31. (PMID: 10344738)
Mol Biotechnol. 2012 Jul;51(3):212-20. (PMID: 21979823)
J Gastrointest Cancer. 2019 Dec;50(4):824-837. (PMID: 30136202)
Oncol Lett. 2016 Oct;12(4):2962-2969. (PMID: 27698884)
Urol Oncol. 2019 Oct;37(10):742-748. (PMID: 31053527)
Int J Oncol. 2016 Jan;48(1):99-109. (PMID: 26647656)
Int J Biol Sci. 2018 Oct 5;14(13):1782-1790. (PMID: 30443182)
Cell Physiol Biochem. 2016;40(3-4):567-578. (PMID: 27889771)
Oncol Rep. 2015 Sep;34(3):1231-8. (PMID: 26151392)
Dis Markers. 2017;2017:3276806. (PMID: 28659655)
Int J Biochem Cell Biol. 2016 Dec;81(Pt A):166-173. (PMID: 27640754)
Tumour Biol. 2014 Mar;35(3):2053-62. (PMID: 24122205)
Oncotarget. 2017 Dec 16;9(3):3631-3640. (PMID: 29423071)
J Cell Sci. 2016 Apr 1;129(7):1355-65. (PMID: 26869223)
Eur J Cancer. 1995 Sep;31A(10):1706-9. (PMID: 7488429)
Int J Oncol. 2014 Apr;44(4):1153-62. (PMID: 24504189)
Head Face Med. 2016 Jan 29;12:8. (PMID: 26821610)
Int J Pharm. 2019 Apr 20;561:114-123. (PMID: 30822503)
Proc Natl Acad Sci U S A. 2017 Aug 1;114(31):8366-8371. (PMID: 28716909)
RSC Adv. 2019 Dec 11;9(70):40873-40882. (PMID: 35540044)
Oncol Lett. 2016 Oct;12(4):2728-2733. (PMID: 27698848)
Front Genet. 2020 Apr 22;11:312. (PMID: 32391048)
J Biol Chem. 1981 Jul 10;256(13):7023-7. (PMID: 6787057)
Colloids Surf B Biointerfaces. 2016 Jul 1;143:532-546. (PMID: 27045981)
Nat Commun. 2017 Jan 23;8:14270. (PMID: 28112170)
Matrix Biol. 2017 May;59:3-22. (PMID: 27746219)
Diagn Pathol. 2020 Mar 24;15(1):28. (PMID: 32209138)
Gastroenterology. 2011 Dec;141(6):2076-2087.e6. (PMID: 21925125)
Cell Signal. 2019 Nov;63:109377. (PMID: 31362044)
Oncol Rep. 2016 Nov;36(5):2852-2860. (PMID: 27599396)
EBioMedicine. 2018 Nov;37:68-77. (PMID: 30341039)
Mol Pharm. 2019 Jun 3;16(6):2481-2493. (PMID: 31013093)
BMC Cancer. 2011 Sep 29;11:418. (PMID: 21957977)
PLoS One. 2014 Sep 03;9(9):e106966. (PMID: 25184276)
Genes Dev. 2015 Jan 15;29(2):171-83. (PMID: 25593307)
Sci Rep. 2017 Jul 10;7(1):4930. (PMID: 28694503)
Cells. 2020 May 16;9(5):. (PMID: 32429463)
BMC Cancer. 2014 Jan 13;14:15. (PMID: 24410905)
Oncogene. 2015 Oct 8;34(41):5229-39. (PMID: 25659582)
Am J Pathol. 1999 Feb;154(2):515-23. (PMID: 10027409)
Nat Commun. 2020 May 12;11(1):2376. (PMID: 32398747)
Proc Natl Acad Sci U S A. 2020 May 26;117(21):11432-11443. (PMID: 32381732)
J Mater Chem B. 2020 May 6;8(17):3880-3885. (PMID: 32222753)
BJU Int. 2000 Mar;85(4):514-8. (PMID: 10691836)
Cancer Res. 2012 Mar 15;72(6):1449-58. (PMID: 22271686)
Cancer Res Treat. 2009 Mar;41(1):29-35. (PMID: 19688069)
Nat Commun. 2012 Jun 06;3:883. (PMID: 22673910)
Int J Mol Sci. 2019 Feb 27;20(5):. (PMID: 30818864)
Respir Res. 2017 Apr 12;18(1):58. (PMID: 28403901)
World J Gastroenterol. 2005 Dec 21;11(47):7401-4. (PMID: 16437708)
Oncotarget. 2016 Jul 19;7(29):45538-45546. (PMID: 27323782)
Cell. 2002 Oct 18;111(2):241-50. (PMID: 12408868)
Clin Cancer Res. 2009 Dec 15;15(24):7462-7468. (PMID: 20008845)
Carcinogenesis. 2014 May;35(5):1003-11. (PMID: 24318997)
Adv Cancer Res. 2014;123:231-54. (PMID: 25081532)
J Clin Diagn Res. 2017 Jan;11(1):EC17-EC23. (PMID: 28273973)
Head Neck. 2019 Apr;41(4):950-958. (PMID: 30561155)
Cancer Res. 2012 Jan 1;72(1):365-74. (PMID: 22086849)
Oncogene. 2013 Oct 24;32(43):5186-90. (PMID: 23208496)
Gastric Cancer. 2017 Mar;20(2):341-349. (PMID: 27055559)
Mol Ther. 2020 May 6;28(5):1251-1262. (PMID: 32145203)
Front Oncol. 2018 May 04;8:145. (PMID: 29780748)
Int J Mol Sci. 2020 Jan 03;21(1):. (PMID: 31947887)
Integr Biol (Camb). 2018 Mar 1;10(3):145-158. (PMID: 29450424)
Int J Clin Exp Pathol. 2019 Oct 01;12(10):3961-3967. (PMID: 31933791)
Med Sci Monit. 2016 Dec 06;22:4779-4785. (PMID: 27923017)
J Hematol Oncol. 2018 May 10;11(1):64. (PMID: 29747682)
Cancer Res. 1995 May 1;55(9):1831-5. (PMID: 7537174)
Cancer Sci. 2016 Jul;107(7):991-1000. (PMID: 27176078)
Genes Chromosomes Cancer. 2003 Feb;36(2):129-38. (PMID: 12508241)
J Cancer Res Clin Oncol. 2014 Dec;140(12):2143-56. (PMID: 25009318)
Prostate. 2014 May;74(6):602-17. (PMID: 24615685)
Mol Cancer. 2020 Feb 25;19(1):37. (PMID: 32098629)
Nat Rev Mol Cell Biol. 2014 Dec;15(12):786-801. (PMID: 25415508)
Oncol Rep. 2014 Dec;32(6):2666-72. (PMID: 25269647)
Cancer Res. 2014 May 1;74(9):2630-41. (PMID: 24618343)
Int J Oncol. 2016 Oct;49(4):1343-50. (PMID: 27499099)
Histopathology. 2018 Oct;73(4):559-572. (PMID: 29468726)
Cancer Cell. 2016 Sep 12;30(3):432-443. (PMID: 27593345)
BMC Cancer. 2011 Feb 01;11:49. (PMID: 21284870)
Cancer Res. 2001 Mar 15;61(6):2592-601. (PMID: 11289136)
Cancer Res. 2013 Jul 1;73(13):4112-22. (PMID: 23633482)
Cancer. 2001 Nov 15;92(10):2539-46. (PMID: 11745187)
Pathol Oncol Res. 2019 Apr;25(2):603-609. (PMID: 30387013)
PLoS One. 2012;7(1):e28776. (PMID: 22242150)
Cell Rep. 2017 Aug 15;20(7):1641-1653. (PMID: 28813675)
Front Oncol. 2019 Apr 30;9:309. (PMID: 31114754)
J Cancer. 2017 Jul 1;8(10):1774-1785. (PMID: 28819374)
Front Oncol. 2019 Aug 21;9:802. (PMID: 31497537)
Oncotarget. 2015 Jan 20;6(2):1202-16. (PMID: 25483103)
Stem Cells Int. 2016;2016:2087204. (PMID: 27200096)
Rev Assoc Med Bras (1992). 2010 Jul-Aug;56(4):472-7. (PMID: 20835647)
Int J Cancer. 1996 Apr 22;69(2):79-85. (PMID: 8608987)
Br J Cancer. 2012 Apr 24;106(9):1495-8. (PMID: 22472880)
J Clin Invest. 2011 Mar;121(3):1064-74. (PMID: 21393860)
Cancer Lett. 2019 Dec 28;467:85-95. (PMID: 31593802)
Breast Cancer. 2018 Nov;25(6):698-705. (PMID: 29845398)
Mol Med Rep. 2016 Jun;13(6):5193-9. (PMID: 27121210)
Biomed Pharmacother. 2019 Oct;118:109369. (PMID: 31545229)
J Control Release. 2015 Dec 28;220(Pt A):275-286. (PMID: 26518722)
Hum Pathol. 1997 Jul;28(7):809-14. (PMID: 9224749)
Head Neck. 2018 Nov;40(11):2340-2346. (PMID: 30303590)
Tumour Biol. 2018 May;40(5):1010428318780859. (PMID: 29888653)
Cancer Res. 2020 Oct 1;80(19):4185-4198. (PMID: 32816856)
J Radiat Res. 2017 Nov 1;58(6):816-826. (PMID: 29106581)
Eur J Cancer. 2010 May;46(7):1271-7. (PMID: 20303742)
Front Immunol. 2015 May 06;6:201. (PMID: 25999946)
Blood. 1998 Jun 1;91(11):4282-91. (PMID: 9596677)
Sci Rep. 2017 May 17;7(1):2042. (PMID: 28515423)
Diagn Pathol. 2014 Apr 08;9:79. (PMID: 24708709)
Acta Neurochir (Wien). 2003 Sep;145(9):825-38. (PMID: 14505115)
Sci Rep. 2015 Feb 17;5:8509. (PMID: 25687880)
Br J Cancer. 2014 Jul 15;111(2):365-74. (PMID: 24921913)
Acta Biomater. 2017 Mar 1;50:259-270. (PMID: 27965172)
Cell Motil Cytoskeleton. 1999;43(4):269-87. (PMID: 10423269)
Asian Pac J Cancer Prev. 2020 Sep 01;21(9):2561-2567. (PMID: 32986353)
Histopathology. 2012 Aug;61(2):153-61. (PMID: 22582975)
BMC Cancer. 2013 Apr 08;13:182. (PMID: 23565736)
J Hepatol. 2000 Jan;32(1):78-84. (PMID: 10673070)
Cell Adh Migr. 2017 Sep 3;11(5-6):476-487. (PMID: 27874296)
Cell Death Dis. 2019 Jan 10;10(1):30. (PMID: 30631039)
Oncol Lett. 2020 Dec;20(6):341. (PMID: 33123252)
Cell Signal. 2015 Sep;27(9):1882-94. (PMID: 25979842)
Oncotarget. 2015 May 10;6(13):11465-76. (PMID: 25888636)
Genes Dev. 2006 Jul 1;20(13):1715-20. (PMID: 16818603)
Matrix Biol. 2009 Jul;28(6):336-46. (PMID: 19442729)
Oncol Rep. 2018 Jan;39(1):442-448. (PMID: 29115557)
Jpn J Cancer Res. 1998 Oct;89(10):1033-40. (PMID: 9849582)
Bioessays. 1995 Jan;17(1):17-24. (PMID: 7535522)
Anticancer Res. 2015 Jan;35(1):39-46. (PMID: 25550533)
Oncotarget. 2018 Oct 09;9(79):34876-34888. (PMID: 30405881)
Nucleic Acid Ther. 2020 Oct;30(5):289-298. (PMID: 32379519)
PLoS One. 2016 Jul 27;11(7):e0159716. (PMID: 27463372)
Cancer Discov. 2019 Jan;9(1):96-113. (PMID: 30361447)
Oncogene. 2014 Jan 30;33(5):665-70. (PMID: 23318432)
Cancer Manag Res. 2018 Sep 24;10:3857-3865. (PMID: 30288117)
Lancet. 1993 Mar 20;341(8847):725-6. (PMID: 8095628)
BMC Cancer. 2018 Jan 31;18(1):113. (PMID: 29385995)
Mol Biol Rep. 2019 Dec;46(6):6629-6645. (PMID: 31486978)
Int J Cancer. 2015 Feb 15;136(4):E161-72. (PMID: 25053293)
Oncol Res Treat. 2017;40(4):192-196. (PMID: 28365695)
Proc Natl Acad Sci U S A. 1982 Mar;79(6):1926-9. (PMID: 6952244)
Cell Signal. 2014 Oct;26(10):2234-9. (PMID: 25025570)
Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15444-9. (PMID: 26621726)
Oncol Lett. 2018 Apr;15(4):5627-5633. (PMID: 29552200)
Mol Pathol. 1999 Aug;52(4):189-96. (PMID: 10694938)
Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12160-4. (PMID: 1465456)
Mol Cell Probes. 2015 Dec;29(6):492-499. (PMID: 26038340)
Oncotarget. 2016 May 10;7(19):28670-83. (PMID: 27107424)
J Cell Physiol. 2019 Nov;234(11):19895-19910. (PMID: 30963578)
J Cancer. 2019 Oct 15;10(24):5915-5925. (PMID: 31762801)
J Pathol Clin Res. 2019 Apr;5(2):130-141. (PMID: 30456933)
Eur J Immunol. 1982 Aug;12(8):659-63. (PMID: 7140811)
Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6127-32. (PMID: 23530247)
Biomark Med. 2018 Jan;12(1):45-61. (PMID: 29243496)
Onco Targets Ther. 2016 Jan 21;9:431-44. (PMID: 26855592)
Hum Pathol. 2019 Sep;91:61-68. (PMID: 31279874)
Am J Pathol. 2012 Jul;181(1):257-67. (PMID: 22626806)
J Ovarian Res. 2016 Sep 02;9(1):53. (PMID: 27590006)
Sci Rep. 2018 Dec 17;8(1):17992. (PMID: 30559397)
Int J Cancer. 2015 Sep 15;137(6):1279-90. (PMID: 25683728)
World J Gastroenterol. 2017 Apr 7;23(13):2337-2345. (PMID: 28428713)
Front Immunol. 2020 Feb 04;11:99. (PMID: 32117253)
Biochem Biophys Res Commun. 2017 Jun 03;487(3):709-715. (PMID: 28442344)
Gels. 2020 Sep 30;6(4):. (PMID: 33008082)
FEBS J. 2011 May;278(9):1429-43. (PMID: 21362138)
Genes Dev. 1999 Jan 1;13(1):35-48. (PMID: 9887098)
Sci Rep. 2020 Jun 30;10(1):10597. (PMID: 32606331)
OMICS. 2021 May;25(5):313-332. (PMID: 33961518)
J Biol Chem. 2010 Sep 24;285(39):30170-80. (PMID: 20663884)
Cancer Biol Ther. 2012 Nov;13(13):1276-83. (PMID: 22895075)
J Cell Biol. 2001 May 28;153(5):893-904. (PMID: 11381077)
Oncotarget. 2017 May 11;8(39):65143-65151. (PMID: 29029419)
Cell Commun Signal. 2019 Jul 22;17(1):80. (PMID: 31331331)
Nucleic Acids Res. 1993 Mar 11;21(5):1225-9. (PMID: 8464707)
Int J Oncol. 2012 Jul;41(1):211-8. (PMID: 22552741)
J Oral Maxillofac Pathol. 2019 May-Aug;23(2):267-272. (PMID: 31516234)
FEBS J. 2012 Jun;279(11):2047-59. (PMID: 22498306)
Oncol Lett. 2019 Oct;18(4):3664-3672. (PMID: 31579408)
Oncotarget. 2016 Aug 23;7(34):55572-55584. (PMID: 27487131)
Int J Biol Markers. 2017 Mar 2;32(1):e75-e82. (PMID: 27470135)
Int J Clin Exp Pathol. 2015 Jun 01;8(6):6724-31. (PMID: 26261555)
Clin Cancer Res. 2016 Nov 15;22(22):5592-5604. (PMID: 27267855)
BMC Cancer. 2010 Sep 29;10:517. (PMID: 20920234)
Life Sci. 2016 Oct 1;162:77-86. (PMID: 27569589)
J Invest Dermatol. 2001 Jan;116(1):93-101. (PMID: 11168803)
Cell. 1989 Mar 24;56(6):1057-62. (PMID: 2466575)
J Clin Invest. 2018 Dec 3;128(12):5549-5560. (PMID: 30395540)
Int J Mol Sci. 2017 Aug 24;18(9):. (PMID: 28837080)
Acta Biomater. 2021 Jan 1;119:114-124. (PMID: 33091625)
Asian Pac J Cancer Prev. 2018 Mar 27;19(3):615-623. (PMID: 29580029)
Eur J Immunol. 1980 Oct;10(10):745-9. (PMID: 6968681)
Lab Invest. 2004 Jul;84(7):894-907. (PMID: 15107804)
Onco Targets Ther. 2020 May 04;13:3703-3716. (PMID: 32440140)
Cell. 2008 Jul 11;134(1):62-73. (PMID: 18614011)
Br J Cancer. 2014 Feb 18;110(4):958-66. (PMID: 24300972)
Cancer Biol Ther. 2005 Jul;4(7):740-6. (PMID: 15970685)
Lab Invest. 2000 Aug;80(8):1291-8. (PMID: 10950120)
Nanoscale. 2016 Jun 2;8(22):11543-58. (PMID: 27203688)
Breast Cancer Res. 2012 May 23;14(3):R84. (PMID: 22621373)
Cells. 2019 Mar 30;8(4):. (PMID: 30935014)
Mol Cancer. 2012 Nov 14;11:83. (PMID: 23151220)
Cancer Res. 2017 Jul 15;77(14):3791-3801. (PMID: 28533273)
Front Cell Dev Biol. 2020 Jun 03;8:417. (PMID: 32582701)
BMC Cancer. 2019 Jun 14;19(1):581. (PMID: 31200666)
Genes Dev. 2019 Feb 1;33(3-4):166-179. (PMID: 30692202)
Clin Exp Metastasis. 2005;22(8):663-73. (PMID: 16691370)
Cancer Res. 1994 Jul 15;54(14):3922-8. (PMID: 7518345)
Int J Mol Med. 2020 Jun;45(6):1783-1792. (PMID: 32236608)
Cell Mol Life Sci. 2021 Feb;78(3):949-962. (PMID: 32440711)
Contributed Indexing:: Keywords: CD44; prognosis; regulation; signalling pathways; therapeutic targeting; tumourigenesis
Substance Nomenclature:: 0 (CD44 protein, human)
0 (Hyaluronan Receptors)
Entry Date(s):: Date Created: 20211224 Date Completed: 20220113 Latest Revision: 20231108
Update Code:: 20240105
PubMed Central ID:: PMC8699317
DOI:: 10.3390/biom11121850
PMID:: 34944493
: Czasopismo naukowe

Pełny tekst

CD44, a non-kinase cell surface transmembrane glycoprotein, has been widely implicated as a cancer stem cell (CSC) marker in several cancers. Cells overexpressing CD44 possess several CSC traits, such as self-renewal and epithelial-mesenchymal transition (EMT) capability, as well as a resistance to chemo- and radiotherapy. The CD44 gene regularly undergoes alternative splicing, resulting in the standard (CD44s) and variant (CD44v) isoforms. The interaction of such isoforms with ligands, particularly hyaluronic acid (HA), osteopontin (OPN) and matrix metalloproteinases (MMPs), drive numerous cancer-associated signalling. However, there are contradictory results regarding whether high or low CD44 expression is associated with worsening clinicopathological features, such as a higher tumour histological grade, advanced tumour stage and poorer survival rates. Nonetheless, high CD44 expression significantly contributes to enhanced tumourigenic mechanisms, such as cell proliferation, metastasis, invasion, migration and stemness; hence, CD44 is an important clinical target. This review summarises current research regarding the different CD44 isoform structures and their roles and functions in supporting tumourigenesis and discusses CD44 expression regulation, CD44-signalling pathways and interactions involved in cancer development. The clinical significance and prognostic value of CD44 and the potential of CD44 as a therapeutic target in cancer are also addressed.

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja